DNAY News and Press, Codex DNA Inc. From 04/06/22

SAN DIEGO, April 06, 2022 (GLOBE NEWSWIRE) --  Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today announced its speaker lineup for presentations at SynBioBeta’s Built with Biology Global Conference, which is being held in Oakland, Ca...

Shares of Codex DNA (NASDAQ:DNAY) closed down another ~11% today as the synthetic biology company's Q4 2021 results continue to weigh on the stock. Codex DNA (DNAY) released those results after the market close on March 23. Since then through closing Monday, shares are down 55%...

The following slide deck was published by Codex DNA, Inc. in conjunction with their 2021 Q4 earnings call. For further details see: Codex DNA, Inc. 2021 Q4 - Results - Earnings Call Presentation

Codex DNA's (DNAY -23.3%) Q4 2021 results that missed on both the top and bottom lines have led to a major decline in share price. The company's net loss widened by ~124% to ~$12.5M compared to the prior-year period. Codex DNA was hurt in the quarter by a more than doubling of total operating...

Gainers: Creative Medical Technology CELZ +99%. 4D pharma LBPS +87%. Femasys FEMY +21%. Revelation Biosciences (REVB) +19%. NeuroSense Therapeutics (NRSN) +7%. Losers: Cue Health (HLTH) -17%. Codex DNA (DNAY) -17%. PetVivo (PETV) -14%. Yumanity The...

Codex DNA, Inc. (DNAY) Q4 2021 Earnings Conference Call March 22, 2022 16:30 ET Company Participants Richard Lepke - Director, Investor Relations Todd Nelson - Chief Executive Officer Dan Gibson - Chief Technology Officer Jennifer McNealey - Chief Financial Officer Conference Call Participant...

Image source: The Motley Fool. Codex DNA, Inc. (NASDAQ: DNAY) Q4 2021 Earnings Call Mar 22, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Codex DNA, Inc. (DNAY) Q4 2021 Earnings Call Transcript

Codex DNA press release (NASDAQ:DNAY): Q4 GAAP EPS of -$0.43 misses by $0.06. Revenue of $3.08M (+58.8% Y/Y) misses by $0.75M. Shares -5%. FY 2022 Guidance: Total Revenue expected to be in the range of $19 to $21 million; Gross margin is expected to be in the range of...

SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop synthetic biology systems, today reported financial results for the fourth quarter and year ended December 31, 2021 and provided financial guidance for 2022. “Codex DNA...

Gainers: Semtech Corporation (NASDAQ:SMTC) +4%. Forterra (NASDAQ:FRTA) +4%. Cerus Corporation (NASDAQ:CERS) +4%. Inspirato Incorporated (NASDAQ:ISPO) +4%. Infinera Corporation (NASDAQ:INFN) +4%. Losers: Codex DNA (NASDAQ:DNAY) -6%. CureVac  (NASDAQ:CVAC) -5%. CarParts...